Share

April 2015; 2 (2) Clinical/Scientific NotesOpen Access

Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis

Machteld E. Hillen, Stuart D. Cook, Arun Samanta, Evan Grant, James R. Quinless, Jamuna K. Rajasingham
First published February 12, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000072
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1486

Share

This article has a correction. Please see:

Article Information

vol. 2 no. 2 e72
DOI: 
https://doi.org/10.1212/NXI.0000000000000072
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 28, 2014
  • Accepted in final form January 12, 2015
  • First Published February 12, 2015.
Copyright & Usage: 
© 2015 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Machteld E. Hillen, MD,
    2. Stuart D. Cook, MD,
    3. Arun Samanta, MD,
    4. Evan Grant, MD,
    5. James R. Quinless, ANP and
    6. Jamuna K. Rajasingham, MD
  1. Machteld E. Hillen, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Roche (2) Biogen Idec, Inc. (3) Novartis Pharmaceuticals, Corporation

    Research Support, Government Entities:

    1. (1) NIH/NINDS, grant number 2R01NS077946, co-investigator, 10/1/12-09/30/17

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) CDHI Foundation, Inc.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Stuart D. Cook, MD,
    3. Scientific Advisory Boards:

    1. (1) Bayer Healthcare (2) Merck Serono (3) Actinobac Biomed (4) Teva Pharmaceuticals (5) Biogen Idec

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology Reviews, Editor, 1997-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Merck Serono (2)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Merck Serono (2) Bayer Healthcare (3) Biogen Idec (4) Roche (5) Novartis Pharmaceuticals

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Arun Samanta, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Vertex Pharmaceuticals: Speaker honorarium Gilead Pharmaceuticals: Speaker honorarium

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Vertex Pharmaceuticals: Speakers' Bureau Gilead Pharmaceuticals: Speakers' Bureau

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Evan Grant, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. James R. Quinless, ANP and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1)Merck-Serono 2)Bayer HealthCare 3)Roche 4)Biogen 5)Novartis Pharmaceuticals

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1)National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Jamuna K. Rajasingham, MD
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology and Neurosciences (M.E.H., S.D.C., J.R.Q.) and Department of Medicine (A.S.), Rutgers-NJMS, Newark, NJ; Department of Physical Medicine and Rehabilitation (E.G.), NYU Langone Medical Center, New York, NY; and Hackensack University Medical Center (J.K.R.), Hackensack, NJ.
  1. Correspondence to Dr. Hillen: machteld.hillen{at}rutgers.edu
View Full Text

Article usage

Article usage: February 2015 to January 2023

AbstractFullPdfSource
Feb 2015591411Highwire
Mar 2015761712Highwire
Mar 2015020pmc
Apr 201513125654Highwire
Apr 201506127pmc
May 2015945511Highwire
May 201502321pmc
Jun 2015394516Highwire
Jun 201503419pmc
Jul 201531311Highwire
Jul 201501516pmc
Aug 201560611Highwire
Aug 201502114pmc
Sep 20151663Highwire
Sep 201502821pmc
Oct 20151446Highwire
Oct 201502218pmc
Nov 201512102Highwire
Nov 201502222pmc
Dec 20151252Highwire
Dec 201501313pmc
Jan 20161662Highwire
Jan 201602432pmc
Feb 2016532Highwire
Feb 201604752pmc
Mar 2016503Highwire
Mar 201604149pmc
Apr 20161427Highwire
Apr 201603652pmc
May 20162247Highwire
May 201603853pmc
Jun 201633114Highwire
Jun 201604052pmc
Jul 20162008Highwire
Jul 201603546pmc
Aug 20162077Highwire
Aug 201603850pmc
Sep 2016900Highwire
Sep 201603641pmc
Oct 201642619Highwire
Oct 201604656pmc
Nov 201626210Highwire
Nov 20160199pmc
Dec 20161625Highwire
Dec 20160164pmc
Jan 20171023Highwire
Jan 201701210pmc
Feb 2017851Highwire
Feb 201701410pmc
Mar 20171416Highwire
Mar 201703144pmc
Apr 2017822Highwire
Apr 201744733pmc
May 20179100Highwire
May 201740427pmc
Jun 2017311Highwire
Jun 2017265pmc
Jul 2017824Highwire
Jul 2017381336pmc
Aug 2017661Highwire
Aug 2017181019pmc
Sep 2017422Highwire
Sep 201721112pmc
Oct 2017600Highwire
Oct 201711314pmc
Nov 2017320Highwire
Nov 201771514pmc
Dec 2017161Highwire
Jan 2018282Highwire
Feb 2018072Highwire
Mar 20182100Highwire
Apr 20180581Highwire
Apr 20180837pmc
May 20184425Highwire
Jun 20181372Highwire
Jun 20181635pmc
Jul 20180333Highwire
Aug 20181151Highwire
Aug 201801043pmc
Sep 20180122Highwire
Oct 20184182Highwire
Nov 20180140Highwire
Dec 20180190Highwire
Jan 20190152Highwire
Feb 2019191Highwire
Mar 2019482Highwire
Apr 20194101Highwire
May 20192244Highwire
Jun 20193162Highwire
Jul 20191146Highwire
Aug 2019284Highwire
Sep 2019173Highwire
Oct 20190141Highwire
Nov 20192184Highwire
Dec 20190121Highwire
Jan 20203166Highwire
Feb 20200132Highwire
Mar 20202176Highwire
Apr 2020082Highwire
May 2020294Highwire
Jun 2020060Highwire
Jul 2020142Highwire
Aug 2020040Highwire
Sep 20202116Highwire
Oct 2020376Highwire
Nov 2020163Highwire
Dec 2020191Highwire
Jan 20214156Highwire
Feb 2021061Highwire
Mar 2021582Highwire
Apr 2021466Highwire
May 2021082Highwire
Jun 202142111Highwire
Jul 20212107Highwire
Aug 20214234Highwire
Sep 20212125Highwire
Oct 202121317Highwire
Nov 202101510Highwire
Dec 20210217Highwire
Jan 20221113Highwire
Feb 20222102Highwire
Mar 20224163Highwire
Apr 20220123Highwire
May 202221810Highwire
Jun 20222113Highwire
Jul 20221112Highwire
Aug 20221263Highwire
Sep 202222514Highwire
Oct 20222285Highwire
Nov 202205515Highwire
Dec 20222179Highwire
Jan 20230317Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me